

TABLE S3. AEs Regardless of Causality Occurring in $\geq 1\%$ of Subjects by Treatment Cycle

	Occurring Over Entire Cycle			Occurring up to 12 weeks after injection		
	Treatment Cycle 1 (n = 2380)	Treatment Cycle 2 (n = 882)	Treatment Cycle 3 (n = 568)	Treatment Cycle 1 (n = 2380)	Treatment Cycle 2 (n = 882)	Treatment Cycle 3 (n = 568)
Subjects with ≥ 1 treatment-emergent AE	831 (34.9)	267 (30.3)	118 (20.8)	707 (29.7)	203 (23.0)	112 (19.7)
Headache	132 (5.5)	17 (1.9)	14 (2.5)	121 (5.1)	15 (1.7)	14 (2.5)
Injection site pain	88 (3.7)	18 (2.0)	7 (1.2)	88 (3.7)	18 (2.0)	7 (1.2)
Nasopharyngitis	85 (3.6)	32 (3.6)	5 (0.9)	53 (2.2)	13 (1.5)	5 (0.9)
Injection site erythema	71 (3.0)	24 (2.7)	8 (1.4)	71 (3.0)	22 (2.5)	8 (1.4)
Injection site edema	56 (2.4)	21 (2.4)	9 (1.6)	56 (2.4)	21 (2.4)	9 (1.6)

Erythema	55 (2.3)	3 (0.3)	1 (0.2)	55 (2.3)	3 (0.3)	1 (0.2)
Edema	46 (1.9)	4 (0.5)	–	46 (1.9)	4 (0.5)	–
Sinusitis	37 (1.6)	9 (1.0)	3 (0.5)	20 (0.8)	7 (0.8)	3 (0.5)
Urinary tract infection	30 (1.3)	11 (1.2)	3 (0.5)	24 (1.0)	10 (1.1)	3 (0.5)
Upper respiratory tract infection	30 (1.3)	19 (2.2)	6 (1.1)	16 (0.7)	12 (1.4)	6 (1.1)
Influenza	25 (1.1)	10 (1.1)	2 (0.4)	10 (0.4)	6 (0.7)	2 (0.4)
Eyelid ptosis	24 (1.0)	7 (0.8)	4 (0.7)	24 (1.0)	7 (0.8)	4 (0.7)
Injection site bruising	21 (0.9)	11 (1.2)	1 (0.2)	21 (0.9)	10 (1.1)	1 (0.2)

AE, adverse event.